Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Merck
US Department of Justice
Boehringer Ingelheim
Covington

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,790,641

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,790,641
Title:Production of high mannose proteins in plant culture and therapeutic uses thereof
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Inventor(s): Shaaltiel; Yoseph (Kibbutz HaSolelim-Doar-Na HaMovil, IL), Baum; Gideon (D.N. Upper Galilee, IL), Bartfeld; Daniel (Moran-Doar-Na Bikat Beit HaKerem, IL), Hashmueli; Sharon (Ramot-Naftali, IL), Lewkowicz; Ayala (Kfar-Vradim, IL)
Assignee: Protalix Ltd. (Carmiel, IL)
Application Number:12/385,894
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,790,641

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer ELELYSO taliglucerase alfa POWDER;INTRAVENOUS 022458-001 May 1, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD OF TREATING GAUCHER'S DISEASE ➤ Sign Up
Pfizer ELELYSO taliglucerase alfa POWDER;INTRAVENOUS 022458-001 May 1, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE. ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,790,641

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel155588Apr 27, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
US Department of Justice
Teva
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.